These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7587036)

  • 1. The role of cefotaxime in the treatment of surgical infections.
    Wittmann DH
    Diagn Microbiol Infect Dis; 1995; 22(1-2):173-82. PubMed ID: 7587036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefotaxime in the treatment of prophylaxis of surgical infections.
    Wittmann DH; Jones RN; Malledant J; Privitera G
    J Chemother; 1997 May; 9 Suppl 2():19-33. PubMed ID: 9248973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic options for cefotaxime in the management of bacterial infections.
    Raddatz JK; Ostergaard BE; Rotschafer JC
    Diagn Microbiol Infect Dis; 1995; 22(1-2):77-83. PubMed ID: 7587054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics.
    Nix DE; Schentag JJ
    Diagn Microbiol Infect Dis; 1995; 22(1-2):71-6. PubMed ID: 7587053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefotaxime in the treatment of staphylococcal infections. Comparison of in vitro and in vivo studies.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1995; 22(1-2):195-201. PubMed ID: 7587040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review.
    Jones RN
    Diagn Microbiol Infect Dis; 1995; 22(1-2):19-33. PubMed ID: 7587039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The in vitro activity of cefotaxime versus bacteria involved in selected infections of hospitalized patients outside of the intensive care unit.
    Doern GV
    Diagn Microbiol Infect Dis; 1995; 22(1-2):13-7. PubMed ID: 7587027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefotaxime use in pediatric infections.
    Dajani AS
    Diagn Microbiol Infect Dis; 1995; 22(1-2):105-10. PubMed ID: 7587022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime.
    Turnidge JD
    Diagn Microbiol Infect Dis; 1995; 22(1-2):57-69. PubMed ID: 7587052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms.
    Francke EL; Neu HC
    Am J Med; 1981 Sep; 71(3):435-42. PubMed ID: 6269426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.
    Jones RN; Thornsberry C
    Rev Infect Dis; 1982; 4 Suppl():S300-15. PubMed ID: 6294779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
    Brogden RN; Spencer CM
    Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.
    Craig WA
    Diagn Microbiol Infect Dis; 1995; 22(1-2):89-96. PubMed ID: 7587056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility tests with cefotaxime and correlation with clinical bacteriologic response.
    Thornsberry C; Jones RN; Barry AL; Fuchs PC
    Rev Infect Dis; 1982; 4 Suppl():S316-24. PubMed ID: 6294780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antimicrobial activity of cefodizime against clinical isolates].
    Suzuki Y; Ishihara R; Ishii Y; Nakazawa A; Deguchi K; Matsumoto Y; Nishinari C; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1996 Oct; 49(10):947-65. PubMed ID: 8986558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Microbiologic and clinical significance of cefotiam].
    Tauchnitz C; Ezold R; Bauer I; Berger HD; Buhl C; Goedecke A; Morawietz I
    Z Gesamte Inn Med; 1985 Mar; 40(5):143-8. PubMed ID: 3857792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates.
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2004 Aug; 49(4):283-7. PubMed ID: 15313534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Susceptibility of bacteria to selected cephalosporins of the II and III generation].
    Nowakowska K; Szozda G; Pawluch D; Drejewicz H; Siwińska-Gołebiowska H
    Med Dosw Mikrobiol; 1993; 45(2):177-82. PubMed ID: 8309293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.